Effect of somatostatin on β-endorphin release in rat experimental chronic inflammation

Massimiliano M. Corsi, Alessandro Fulgenzi, Mario Tiengo, Giulio Pravettoni, Gianfranco Gaja, Maria Elena Ferrero

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The aim of the present study was to investigate the effect of somatostatin administration in arthritic rats. Inflammation was induced by daily interplantar injection of 100 μl of Freund's complete adjuvant into the left hind paw of the rat. Arthritis developed 20 days following the first injection and was stable in the inoculate paw. Arthritic rats were treated interplantarly with somatostatin (5 or 10 μg) or with indomethacin (100 μg) daily for 14 days. Inflammatory response was studied at 12 h, 7 and 14 days following drug administration. The effect of somatostatin was determined by local (into popliteal lymph nodes) and systemic production of β-endorphin. Our results showed that somatostatin treatment significantly increased β- endorphin levels in the blood and lymphocytes from popliteal lymph nodes. Greater efficiency was seen when 5 μg instead of 10 μg of somatostatin was used. A significant decrease of absolute leukocytosis was observed at the 14th day following somatostatin administration. Moreover, a significant reduction of plasmatic β-globulins at 12 h and the 7th day and of plasmatic α2-globulins at the 14th day was observed after the beginning of somatostatin treatment.

Original languageEnglish
Pages (from-to)2247-2254
Number of pages8
JournalLife Sciences
Volume64
Issue number24
DOIs
Publication statusPublished - May 7 1999

Fingerprint

Endorphins
Somatostatin
Rats
Inflammation
Arthritis
Globulins
Lymph Nodes
Injections
Lymphocytes
Freund's Adjuvant
Leukocytosis
Indomethacin
Blood
Therapeutics
Pharmaceutical Preparations

Keywords

  • β-endorphin
  • Arthritis
  • Chronic inflammation
  • Plasma proteins
  • Somatostatin

ASJC Scopus subject areas

  • Pharmacology

Cite this

Effect of somatostatin on β-endorphin release in rat experimental chronic inflammation. / Corsi, Massimiliano M.; Fulgenzi, Alessandro; Tiengo, Mario; Pravettoni, Giulio; Gaja, Gianfranco; Ferrero, Maria Elena.

In: Life Sciences, Vol. 64, No. 24, 07.05.1999, p. 2247-2254.

Research output: Contribution to journalArticle

Corsi, MM, Fulgenzi, A, Tiengo, M, Pravettoni, G, Gaja, G & Ferrero, ME 1999, 'Effect of somatostatin on β-endorphin release in rat experimental chronic inflammation', Life Sciences, vol. 64, no. 24, pp. 2247-2254. https://doi.org/10.1016/S0024-3205(99)00176-9
Corsi, Massimiliano M. ; Fulgenzi, Alessandro ; Tiengo, Mario ; Pravettoni, Giulio ; Gaja, Gianfranco ; Ferrero, Maria Elena. / Effect of somatostatin on β-endorphin release in rat experimental chronic inflammation. In: Life Sciences. 1999 ; Vol. 64, No. 24. pp. 2247-2254.
@article{02b64f31473e40669210cece051b1bae,
title = "Effect of somatostatin on β-endorphin release in rat experimental chronic inflammation",
abstract = "The aim of the present study was to investigate the effect of somatostatin administration in arthritic rats. Inflammation was induced by daily interplantar injection of 100 μl of Freund's complete adjuvant into the left hind paw of the rat. Arthritis developed 20 days following the first injection and was stable in the inoculate paw. Arthritic rats were treated interplantarly with somatostatin (5 or 10 μg) or with indomethacin (100 μg) daily for 14 days. Inflammatory response was studied at 12 h, 7 and 14 days following drug administration. The effect of somatostatin was determined by local (into popliteal lymph nodes) and systemic production of β-endorphin. Our results showed that somatostatin treatment significantly increased β- endorphin levels in the blood and lymphocytes from popliteal lymph nodes. Greater efficiency was seen when 5 μg instead of 10 μg of somatostatin was used. A significant decrease of absolute leukocytosis was observed at the 14th day following somatostatin administration. Moreover, a significant reduction of plasmatic β-globulins at 12 h and the 7th day and of plasmatic α2-globulins at the 14th day was observed after the beginning of somatostatin treatment.",
keywords = "β-endorphin, Arthritis, Chronic inflammation, Plasma proteins, Somatostatin",
author = "Corsi, {Massimiliano M.} and Alessandro Fulgenzi and Mario Tiengo and Giulio Pravettoni and Gianfranco Gaja and Ferrero, {Maria Elena}",
year = "1999",
month = "5",
day = "7",
doi = "10.1016/S0024-3205(99)00176-9",
language = "English",
volume = "64",
pages = "2247--2254",
journal = "Life Sciences",
issn = "0024-3205",
publisher = "Elsevier Inc.",
number = "24",

}

TY - JOUR

T1 - Effect of somatostatin on β-endorphin release in rat experimental chronic inflammation

AU - Corsi, Massimiliano M.

AU - Fulgenzi, Alessandro

AU - Tiengo, Mario

AU - Pravettoni, Giulio

AU - Gaja, Gianfranco

AU - Ferrero, Maria Elena

PY - 1999/5/7

Y1 - 1999/5/7

N2 - The aim of the present study was to investigate the effect of somatostatin administration in arthritic rats. Inflammation was induced by daily interplantar injection of 100 μl of Freund's complete adjuvant into the left hind paw of the rat. Arthritis developed 20 days following the first injection and was stable in the inoculate paw. Arthritic rats were treated interplantarly with somatostatin (5 or 10 μg) or with indomethacin (100 μg) daily for 14 days. Inflammatory response was studied at 12 h, 7 and 14 days following drug administration. The effect of somatostatin was determined by local (into popliteal lymph nodes) and systemic production of β-endorphin. Our results showed that somatostatin treatment significantly increased β- endorphin levels in the blood and lymphocytes from popliteal lymph nodes. Greater efficiency was seen when 5 μg instead of 10 μg of somatostatin was used. A significant decrease of absolute leukocytosis was observed at the 14th day following somatostatin administration. Moreover, a significant reduction of plasmatic β-globulins at 12 h and the 7th day and of plasmatic α2-globulins at the 14th day was observed after the beginning of somatostatin treatment.

AB - The aim of the present study was to investigate the effect of somatostatin administration in arthritic rats. Inflammation was induced by daily interplantar injection of 100 μl of Freund's complete adjuvant into the left hind paw of the rat. Arthritis developed 20 days following the first injection and was stable in the inoculate paw. Arthritic rats were treated interplantarly with somatostatin (5 or 10 μg) or with indomethacin (100 μg) daily for 14 days. Inflammatory response was studied at 12 h, 7 and 14 days following drug administration. The effect of somatostatin was determined by local (into popliteal lymph nodes) and systemic production of β-endorphin. Our results showed that somatostatin treatment significantly increased β- endorphin levels in the blood and lymphocytes from popliteal lymph nodes. Greater efficiency was seen when 5 μg instead of 10 μg of somatostatin was used. A significant decrease of absolute leukocytosis was observed at the 14th day following somatostatin administration. Moreover, a significant reduction of plasmatic β-globulins at 12 h and the 7th day and of plasmatic α2-globulins at the 14th day was observed after the beginning of somatostatin treatment.

KW - β-endorphin

KW - Arthritis

KW - Chronic inflammation

KW - Plasma proteins

KW - Somatostatin

UR - http://www.scopus.com/inward/record.url?scp=0033532325&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033532325&partnerID=8YFLogxK

U2 - 10.1016/S0024-3205(99)00176-9

DO - 10.1016/S0024-3205(99)00176-9

M3 - Article

VL - 64

SP - 2247

EP - 2254

JO - Life Sciences

JF - Life Sciences

SN - 0024-3205

IS - 24

ER -